Search

Displaying results 1771 - 1780 of 10000 in total
  1. Drug

    Corynebacterium diphtheriae

    go.drugbank.com/drugs/DB09877
    ApprovedInvestigational

    The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … *Corynebacterium diphtheriae* toxin is extracted from the pathogenic actinobacterium *C. diphtheriae* that causes diphtheria.

    Mixtures: Td-pur für Erwachsene und Heranwachsende
  2. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803] … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.

  3. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. … The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.

    Products: E-ZOX
  4. Drug

    Cyclophosphamide

    go.drugbank.com/drugs/DB00531
    ApprovedInvestigational

    Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. … It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep.

  5. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [L1118] It was never approved by the FDA.

    Categories: Sex Hormones and Modulators of the Genital System
  6. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … Momelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.[A261561, A261566, A261571]

  7. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. … It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.

  8. Drug

    Gadopentetic acid

    go.drugbank.com/drugs/DB00789
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) … A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.

  9. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [A234224] Without the activity of the SARS-CoV-2 3CL<sup>PRO</sup>, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication. … mild-to-moderate COVID-19.

  10. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named

    Categories: Antivirals used in combination for the treatment of HIV infections